GlassScriptPhysician profile
Faina M Gutin
NPI 1578666707
$9,339.72
in general payments reported to CMS, 2019-2025
24 companies · $653 in 2025
The $653 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,411 · 2020: $2,903 · 2021: $166 · 2022: $171 · 2023: $329 · 2024: $705 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $3,896.41 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Biocryst Pharmaceuticals, INC. | $1,750.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,091.98 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Optinose US, INC. | $833.95 | 2019-2020 | |
| Glaxosmithkline, LLC. | $538.44 | 2019-2025 | Nucala, Trelegy Ellipta |
| Pharming Healthcare, INC. | $217.11 | 2019-2025 | Ruconest |
| Genzyme Corporation | $204.21 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $124.72 | 2019-2025 | |
| Amgen INC. | $86.18 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $85.31 | 2019-2025 | Dupixent |
| Kaleo, INC. | $84.69 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $76.61 | 2023-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $68.61 | 2020-2024 | Hyqvia, Aralast |
| Biocryst US Sales Co., LLC | $58.79 | 2022-2023 | Orladeyo |
| Pfizer INC. | $39.19 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $32.68 | 2019-2024 | Xembify |
| Greer Laboratories, INC. | $28.35 | 2019 | |
| Shire North American Group INC | $25.15 | 2019 | |
| Bio Products Laboratory USA, INC. | $21.36 | 2019 | |
| Philips North America LLC | $19.80 | 2019 | |
| Cycle Pharmaceuticals INC | $15.66 | 2025 | Sajazir |
| Mylan Specialty L.P. | $15.64 | 2019 | |
| Alk-Abello, INC | $12.97 | 2023 | Ragwitek, Grastek, Odactra |
| Teva Pharmaceuticals USA, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faina Gutin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.